Insider Selling: Phreesia, Inc. (NYSE:PHR) COO Sells 10,716 Shares of Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) COO Evan Roberts sold 10,716 shares of the business's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $27.48, for a total value of $294,475.68. Following the sale, the chief operating officer now owns 764,307 shares of the company's stock, valued at $21,003,156.36. The trade was a 1.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Evan Roberts also recently made the following trade(s):

• On Tuesday, January 21st, Evan Roberts sold 12,749 shares of Phreesia stock. The stock was sold at an average price of $27.31, for a total value of $348,175.19.
• On Wednesday, January 15th, Evan Roberts sold 1,785 shares of Phreesia stock. The stock was sold at an average price of $26.98, for a total value of $48,159.30.
• On Wednesday, January 8th, Evan Roberts sold 2,681 shares of Phreesia stock. The stock was sold at an average price of $27.95, for a total value of $74,933.95.
• On Monday, January 6th, Evan Roberts sold 2,873 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total value of $76,450.53.

Phreesia Stock Performance

Shares of PHR stock traded down $0.53 on Friday, hitting $28.47. 306,682 shares of the stock traded hands, compared to its average volume of 388,179. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The company has a market capitalization of $1.65 billion, a PE ratio of -19.37 and a beta of 0.94. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $29.90. The company's fifty day moving average is $24.98 and its 200 day moving average is $23.28.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. The business had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business's revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.58) EPS. On average, equities research analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Phreesia

Several institutional investors and hedge funds have recently made changes to their positions in the company. Champlain Investment Partners LLC grew its stake in shares of Phreesia by 4.1% in the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company's stock worth $57,062,000 after purchasing an additional 97,847 shares in the last quarter. Sei Investments Co. grew its stake in shares of Phreesia by 135.3% in the second quarter. Sei Investments Co. now owns 165,327 shares of the company's stock worth $3,505,000 after purchasing an additional 95,058 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of Phreesia by 56.3% in the second quarter. Squarepoint Ops LLC now owns 250,396 shares of the company's stock worth $5,308,000 after purchasing an additional 90,215 shares in the last quarter. State Street Corp grew its stake in shares of Phreesia by 7.1% in the third quarter. State Street Corp now owns 1,327,586 shares of the company's stock worth $30,256,000 after purchasing an additional 88,517 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Phreesia by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company's stock worth $28,397,000 after purchasing an additional 55,934 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on PHR. Citigroup upped their price target on Phreesia from $31.00 to $35.00 and gave the stock a "buy" rating in a report on Friday, January 10th. KeyCorp upped their price target on Phreesia from $28.00 to $30.00 and gave the stock an "overweight" rating in a report on Wednesday, January 8th. Robert W. Baird decreased their price target on Phreesia from $34.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, December 11th. Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 target price on shares of Phreesia in a research report on Friday, January 10th. Finally, Royal Bank of Canada raised Phreesia from a "sector perform" rating to an "outperform" rating and upped their target price for the company from $24.00 to $32.00 in a research report on Wednesday, January 8th. Thirteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $31.15.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.